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The use of multimodal computed tomography imaging (MMCT) in routine clinical assess-
ment of stroke patients improves the identification of patients with large regions of salvage-
able brain tissue, lower risk for haemorrhagic transformation, or a large vessel occlusion
requiring endovascular therapy.
Aim
To evaluate the cost-effectiveness of using MMCT compared to usual practice for determin-
ing eligibility for reperfusion therapy with alteplase using real world data from the Interna-
tional Stroke Perfusion Imaging Registry (INSPIRE).
Methods
We performed a cost-utility analysis. Mean costs and quality-adjusted life years (QALYs)
per patient for two alternative screening protocols were calculated. Protocol 1 represented
usual practice, while Protocol 2 reflected treatment targeting using multimodal imaging.
Cost-effectiveness was assessed using the net-benefit framework.
Results
Protocol 1 had a total mean per patient cost of $2,013 USD and 0.148 QALYs. Protocol 2
had a total mean per patient cost of $1,519 USD and 0.153 QALYs. For a range of willing-
ness-to-pay values, representing implicit thresholds of cost-effectiveness, the lower bound
of the incremental net monetary benefit statistic was consistently greater than zero,
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indicating that MMCT is cost- effective compared to usual practice. The results were most
sensitive to variation in the mean number of alteplase vials administered.
Conclusion
In a healthcare setting where multimodal imaging technologies are available and reim-
bursed, their use in screening patients presenting with acute stroke to determine eligibility
for alteplase treatment is cost-effective given a range of willingness-to-pay thresholds and
warrants consideration as an alternative to routine practice.
Introduction
The timely evaluation and diagnosis of ischaemic stroke is important given the narrow thera-
peutic time window in which intravenous recombinant tissue plasminogen activator (IV-tPA)
should be administered [1]. Current protocols for evaluation and diagnosis of acute stroke rec-
ommend the use of non-contrast brain computed tomography (NCCT). However more
sophisticated neuroimaging is available in the form of CT perfusion (CTP) and CT angiogra-
phy (CTA). Acute CTP has been validated to identify subgroups of ischemic stroke patients
who receive the most benefit from reperfusion therapy [2, 3] as well as those who may be
harmed due to haemorrhagic transformation [4]. Additionally, advanced imaging can identify
patients with a low probability of benefit from intravenous reperfusion therapy because their
ischaemic lesion is too severe or there is minimal tissue to salvage. In this era of more personal-
ised medicine, it is appropriate to consider the impact of targeted stroke therapy not only on
individual patient outcomes but on the cost of the additional assessments to the health care
system.
The cost-effectiveness of thrombolysis for acute ischaemic stroke is well established [5–7].
However, there is limited published information on the cost-effectiveness of multimodal CT
(MMCT) for targeting patients suitable to receive intravenous reperfusion therapy. Young
et al. [8] present a modelled economic analysis comparing MMCT to NCCT as an alternative
tool for determining eligibility for endovascular therapy in a hypothetical cohort of non-hae-
morrhagic stroke patients using data extracted from the clinical literature. The results from
their analysis showed that over a 3-month follow-up, MMCT was cost saving in comparison to
NCCT (-$1,716 USD) and associated with greater quality-adjusted life-years (QALYs, 0.004).
The authors concluded that given a willingness-to-pay (WTP) threshold of $100,000/QALY
USD, MMCT represented a cost-effective choice. However, cost-effectiveness of MMCT has
not been assessed using real-world data.
Aims
Using data from the International Stroke Perfusion Imaging Registry (INSPIRE), administered
by the University of Newcastle Stroke Research Program (UNSRP), we investigated the cost
and cost-effectiveness of targeted reperfusion therapy for acute ischaemic stroke patients by
comparing two alternative reperfusion treatment selection protocols. Protocol 1, representing
usual practice, relies on non-contrast CT (NCCT), CT-angiography (CTA) and clinician judg-
ment, while protocol 2 reflects treatment targeting using multimodal imaging (NCCT, CTA
and CTP) to identify the ideal target for reperfusion therapy.
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Methods
We undertook a cost-utility analysis using a decision analytic framework to compare the costs
and outcomes of two alternative reperfusion treatment selection protocols applied to the same
population of patients with an acute ischaemic stroke presentation (Fig 1). Cost utility analysis
allows comparison of interventions both within and between disease areas by using outcome
measures that combine length of life and quality of life into a single summary measure, the
quality adjusted life year (QALY). In this approach, states of health are assigned a health state
preference or ’utility’ value. The amount of time an individual spends in a given health state is
multiplied by the health state preference value to calculate the quality-adjusted life-years
(QALYs) gained.
The analysis was based on patient level data from INSPIRE [9]. The outcome measure was
90-day QALYs, calculated using transformed modified Rankin Score (mRS) data from
INSPIRE. Resource use was estimated according to the respective treatment protocols and
Australian unit costs were applied. Costs were calculated in 2016 Australian dollars and pre-
sented in 2016 US dollars using a purchasing power parity of $1 AUS = $0.69 US [10]. Cost-
effectiveness was assessed using the net-benefit framework calculating an incremental net
monetary benefit statistic. The time horizon for the analysis was three months post stroke
event reflecting the available functional outcome assessment data included in INSPIRE.
Fig 1. Decision analytic model structure.
https://doi.org/10.1371/journal.pone.0206203.g001
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Extrapolation was not undertaken because stroke outcomes are well established at 3-months
follow-up.
Study population
Consecutive acute ischemic stroke patients presenting to hospital within 4.5 hours of symptom
onset at five centres ([1] John Hunter Hospital, NSW, Australia; [2] Gosford Hospital, NSW,
Australia; [3] Huashan Hospital, Shanghai, China; [4] the Second Affiliated Hospital of Zhe-
jiang University, Hangzhou, China; and [5] Sunnybrook Health Science Centre, Toronto, Can-
ada) between 2011–2014 were prospectively recruited to INSPIRE. Patients underwent
baseline (within 4.5 hours of stroke onset) MMCT imaging and follow-up imaging at 24 hours
post-stroke. Clinical stroke severity was assessed at the two imaging time points using the
National Institutes of Health Stroke Scale (NIHSS). Eligible patients were treated with intrave-
nous thrombolysis according to local guidelines and the clinical judgement of the treating phy-
sician. The modified Rankin scale (mRS) was assessed 90 days after stroke. Written informed
consent was obtained from all participants, and the INSPIRE study was approved by the local
ethics committees in accordance with Australian National Health & Medical Research Council
(NHMRC) guidelines. The analysis was conducted in Newcastle, Australia, the site of the
INSPIRE study and database. Patients undergoing endovascular procedures were not enrolled
in the INSPIRE database during this time period. Retrospective CTP analysis of the patient
population was conducted to classify patients into treatment or no treatment groups for the
MMCT treatment targeting applied in protocol 2.
CTP analysis and classification of patients
All perfusion imaging was post processed on commercial software MIStar (Apollo Medical
Imaging Technology, Melbourne, Australia). The acute MMCT protocol is described in detail
in S1 File. Acute perfusion imaging was processed using single value deconvolution with delay
and dispersion correction [11]. Previously validated thresholds were applied in order to mea-
sure the volume of the acute perfusion lesion (relative delay time, DT>3 seconds) and acute
infarct core (relative CBF <30%) [12]. Penumbral volume was calculated from the volume of
the perfusion lesion (DT threshold >3 seconds) minus the volume of the infarct core (relative
CBF threshold <30% within the DT >3sec lesion), the volume of severely hypoperfused tissue
(DT>6sec) was also recorded for haemorrhage prediction. The mismatch ratio was deter-
mined as the ratio of the perfusion lesion volume (DT>3sec to the volume of the ischemic
core (DT>3sec, CBF<30%).
Following post processing, patients were categorised into one of four groups [2]:
1. Large core—A large infarct core>70mL on acute CTP.
2. No target—Lack of significant perfusion lesion-core ‘mismatch’. This was determined as
the measured ratio of perfusion lesion to core. If a patient had a ratio of<1.2, they were
considered to have no mismatch.
3. Small lesion—A small perfusion lesion, any patient with a perfusion lesion of<5mL [13].
Overlapping patients who had a small perfusion lesion and no mismatch were considered
to be in the small perfusion lesion group.
4. Ideal target—Target mismatch patients who were considered ideal candidates for reperfu-
sion therapy. We used the DEFUSE 2 mismatch criteria of and absolute mismatch volume
>15mL, mismatch ratio >1.8, a baseline ischemic core <70mL, and volume of severely
hypoperfused tissue <100mL.
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In the economic analysis, we assumed for protocol 1 that all patients would have one NCCT
test and one CTA test. The probability of receiving rtPA reflected the proportion of treated
patients observed in the INSPIRE data (Table 1). For protocol 2, we assumed all patients
would receive NNCT, CTA and CTP and only patients categorised in subgroup 4 (ideal target)
would receive rtPA.
Measurement of outcomes
From INSPIRE, we extracted 90-day modified Rankin Scale (mRS) data for each patient in the
dataset. These health outcomes, including mortality, were transformed into utilities using the
algorithm published by Ramos-Goni et al [14]. In the absence of Australian specific values in
the algorithm, we used the value set for the UK population to calculate mean utilities [15]. We
calculated individual utility values for each patient in the dataset. An mRS score of 6, indicat-
ing death was appropriately mapped to a utility of zero. Mean utility was calculated for the
whole cohort, for each of the four treatment target groups (1. Large core, 2. No target, 3. Small
lesion, 4. Ideal target) and for the treated and untreated subgroups within the four groups
(Table 1).
For protocol 1, we used the patient level utility values calculated using the method described
above. These values reflect the expected utility for a cohort of patients whose actual treatment
determination and outcome align to protocol 1. The outcomes associated with protocol 2 in
the decision analysis, were directly aligned with treatment status. Due to variation in local phy-
sician preference and institutional guidelines, some patients in group 4 were not treated and
some patients in categories 1, 2 and 3 were treated [2]. Therefore, we undertook the following
steps for calculating mean utility for the cohort described under protocol 2:
i. Treated patients in group 4 retained their transformed utilities (calculated as for protocol 1).
Untreated patients in group 4 had their utility values imputed using the mean utility calcu-
lated for the treated subgroup (calculated under protocol 1).
ii. Untreated patients in groups 1, 2 and 3 retained their transformed utilities (calculated as
for protocol 1). Treated patients in groups 1, 2 and 3 had their utility values imputed from
the mean utility values calculated for the untreated subgroups from each group (1, 2 and 3,)
respectively.
Table 1. Patient characteristics from INSPIRE.
1. Large 2. No target 3. Small 4. Ideal
N (Total 1518) 228 504 408 378
Proportion died 37% 18% 2% 8%
Treated N (%) 161 (70%) 354 (70%) 166 (40%) 256 (70%)
Mean age
Treated 56 63 52 73
Not treated 59 59 66 72
% Males
Treated 49% 54% 58% 46%
Not treated 58% 61% 51% 54%
Mean transformed utility
Treated 0.26 0.60 0.77 0.61
Not treated 0.25 0.63 0.83 0.52
Difference (95% UI) (0.0899, 0.0940)
https://doi.org/10.1371/journal.pone.0206203.t001
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The average number of QALYs for each of the protocols was calculated by multiplying the
mean utility across the cohort by 90/365.
Measurement and valuation of costs
For each patient in the INSPIRE cohort and for each protocol, we calculated the cost of imag-
ing and treatment, valued using the 2016 Medicare Benefit Schedule fee and the cost of treat-
ment with alteplase. Treatment cost was calculated as the cost of two packs (1 x 50 mg vial, 1 x
50 mL inert diluent), reflecting the recommended dose of 0.9 mg/kg body weight (maximum
of 90 mg) and including an allowance for wastage. In protocol 1, the costs included NCCT
imaging for all patients and the cost of treatment with 50mg alteplase if indicated in the data-
set. In protocol 2, the costs included MMCT imaging for all patients and the cost of treatment
with 50mg alteplase only for category 4 (Ideal) patients.
Statistical analysis
We undertook the cost-effectiveness analysis from the health care funder perspective. All anal-
yses were carried out using Microsoft Excel 2013. Mean costs and outcomes were compared
across each of the two alternative protocols. We used the net-benefit framework to report the
cost-effectiveness results, calculating an incremental net monetary benefit (iNMB) statistic.
The iNMB in this analysis was calculated as the difference in mean QALYs per patient multi-
plied by the maximum willingness-to-pay for a QALY, minus the difference in mean cost per
patient. We used the cost-effectiveness threshold range $20,690 –$62,069 USD as the lower
and upper limits of the maximum willingness to pay for a QALY (W), reflecting implicit
threshold ranges reported in the literature [16].
Cost-effectiveness results presented using the net- benefit framework have the advantage of
being simple to interpret. If the lower bound of the incremental net benefit statistic is greater
than zero (iNMB>0), the intervention in question should be adopted [17].
Uncertainty and sensitivity analysis
We accounted for uncertainty in the analysis using nonparametric bootstrapping to derive
uncertainty intervals (UI) around the point estimates. We also conducted sensitivity analysis
to examine the impact of variation in the treatment cost and tested the impact of using differ-
ence preference weights to generate utility values.
Results
Study population characteristics
The INSPIRE data set included age, sex, resource use frequency data and outcome variables
for a total of 1,518 stroke patients. Patient characteristics and calculated utilities according to
MMCT assigned category, representing protocol 1, are presented in Table 1. The utility values
of the treated and non-treated sub groups do not vary significantly across the categories with
the exception of category 4 (ideal) where the calculated utility value for treated patients is
higher (mean utility difference p< .05).
Costs and cost-effectiveness
Mean total costs per patient were $2,013 USD (95% UI $1,951 to $2,061) for protocol 1 and
$1,519 for protocol 2 (Table 2). The difference in cost is driven by a reduction in the number
of patients receiving treatment under protocol 2. Mean total QALYs per patient were calcu-
lated to be 0.148 (95% UI 0.144, 0.152) for protocol 1 and 0.153 (95% UI 0.152, 0.155) for
Cost-effectiveness of MMCT in optimal patient selection for thrombolytic therapy
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protocol 2. The mean incremental net monetary benefit (iNMB) between the two protocols, at
willingness-to-pay thresholds of $20,690 USD per QALY and $62,069 USD, were $640 (95%
UI $479, $705) and $935 (95% UI $526, $1,076), respectively (Table 2). Since the lower bound
of the iNMB, for either WTP threshold, is greater than zero, these results show that MMCT is
the cost-effective alternative. The net benefit curve (Fig 2) depicts the expected change in net
benefit associated with increasing WTP thresholds.
Sensitivity analysis
The results were most sensitive to variation in the treatment cost, modelled by varying the
mean number of vials of alteplase administered. The higher the treatment cost, the greater the
Table 2. Mean costs per patient, utility values and QALYs.
Protocol 1 –Current treatment selection Protocol 2 –MMCT treatment targeting
Mean cost (USD) Mean cost (USD)
Imaging $486 $904
Treatment $1,527 ($1,465, $1,582) $616
Total cost (95% UI) $2,013 ($1,951, $2,061) $1,519
90 day QALYs (95% UI) 0.148 (0.144, 0.152) 0.153 (0.152, 0.155)
Incremental net monetary benefit (iNMB)
WTP threshold $20,690 USD (95% UI) $640 ($479, $705)
WTP threshold $62,069 USD (95% UI) $935 ($526, $1,076)
Abbreviations: QALY, quality adjusted life year; UI, uncertainty interval; WTP, willingness to pay; USD, US dollars
https://doi.org/10.1371/journal.pone.0206203.t002
Fig 2. Net benefit curve.
https://doi.org/10.1371/journal.pone.0206203.g002
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incremental net benefit (Fig 3). Varying the utilities between the minimum and maximum
range, reflecting different country preference weights, also resulted in higher iNMB estimates
(Fig 3).
Discussion
Our economic analysis based on data from INSPIRE, showed that the additional costs to the
health system incurred by MMCT are offset due to fewer patients requiring treatment with IV-
rtPA. That is, screening with MMCT is cost saving. Furthermore, the analysis showed that
these cost savings are achieved with no loss in utility. This resulted in a positive incremental
net monetary benefit when compared against a range of maximum willingness-to-pay thresh-
olds for a QALY [16]. Our analysis results are consistent with the findings from the only other
published economic analysis evaluating MMCT identified in the literature (5). The Young
et al. analysis showed that MMCT had lower costs, greater QALYs and was the cost-effective
choice 100% of the time for a willingness-to-pay of $100,000/QALY USD. The main strength
of our analysis is the use of real world, patient level data captured across multiple international
sites contributing to INSPIRE. The data registry provided information on stroke severity and
respective treatment groups, as well as mRS values from which we could calculate utility
scores.
In the present study we divided patients into one of four groupings based on previous work
suggesting futile treatment with alteplase in large ischemic cores, a good natural history of
patients with small or no perfusion lesion (which includes possible stroke mimics), patients
not suspected to benefit from alteplase (no mismatch), and ’ideal’ alteplase candidates (target
mismatch). The clinical outcome information from the QALY reinforce these groupings and
suggest that considering alternate forms of reperfusion therapy for patients with large ischemic
cores or no mismatch, such as endovascular therapy, may be ideal. Alteplase therapy poses sev-
eral risks, particularly of haemorrhagic transformation, which is most amplified in select
groups of patients, those with large infarct cores. However, this notion is currently being
Fig 3. Sensitivity analysis results.
https://doi.org/10.1371/journal.pone.0206203.g003
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challenged in patients receiving endovascular therapy. In this study, patients with an ideal
imaging target demonstrated the greatest cost effective treatment response to intravenous
thrombolysis due to a dramatic reduction in their disability at 3 months. Our data suggests
that a targeted treatment approach where patients with an ideal imaging profile with alteplase
and/or endovascular therapy, if appropriate, leads to improved clinical outcomes over an
approach of treating all suspected ischemic stroke patients [2, 18]. Such a targeted treatment
approach may result in the best possible patient outcomes and be particularly cost effective,
due in large part to the role of imaging selection in patient management and the improved
patient outcomes with or without interventions, resulting in long term cost benefits through
reduced burden of care.
A number of limitations should also be recognised. Not every country, health district or
hospital will have access to the imaging technologies employed in the analysis and the cost pro-
file reflects the study jurisdiction. Hence, we recognise that these results will not have universal
applicability and that targeting treatment using MMCT may not be cost saving in other set-
tings. Further, there are a number of technical limitations. First, the omission of the cost of
hospital stay. Any variation in length of stay or intensity of resource use was therefore not cap-
tured and may bias the findings. Second, we derived the utility values based on a transforma-
tion of the mRS data. Ideally, utility values should be directly elicited. Third, patients in this
analysis were divided into groups based on imaging profiles and the results do not stem from
patients’ random allocation to treatment. The probability of receiving treatment under Proto-
col 1 will have included such factors as patient age and co-morbidities. The patient characteris-
tics data that were available (Table 1) show that the mean age of the treated and untreated
cohorts in each of the groups do not systematically bias the results. While data on patient co-
morbidities were unavailable for this analysis, the use of propensity score matching based on
these data would be an option to explore in any future analysis to mitigate the risk of bias.
Conclusion
Compared to current practice, defined as non-contrast CT (NCCT), CT-angiography (CTA)
and clinician judgment, MMCT is a cost effective screening tool when used to target patients
for rtPA treatment. This analysis showed that under conservative scenarios, MMCT can be
cost saving with no loss in clinical or quality of life outcomes.
Supporting information
S1 File. Acute multimodal CT protocol.
(PDF)
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